Repeat testing of lipoprotein(a) (Lp(a)) is often unnecessary, particularly for individuals outside of risk thresholds.
For those near thresholds or receiving Lp(a)-lowering therapies, reconsidering repeat testing may be beneficial.
Intraindividual variability analysis highlights stable levels of Lp(a) in most individuals across time frames.
Thus, clinicians should weigh the need for repeated assessments based on individual risk factors and therapeutic goals.
Resumen
Hence, repeat Lp(a) testing is generally unnecessary but could be considered in those near risk thresholds or those being evaluated for Lp(a)-lowering therapies.